Veterinary medicines in 2025

HMA/EMA multi-stakeholder workshop on artificial intelligence (AI), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 November 2025, 13:00 (CET) to 21 November 2025, 12:50 (CET)

Submission deadlines for orphan designations

Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 3, Status: Authorised

Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications 2026-2027

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 4, Status: Authorised

EMEA-002036-PIP01-16

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Zercepac, trastuzumab, Date of authorisation: 27/07/2020, Revision: 14, Status: Authorised